Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs REMEVi

By GLP-1 ScorecardUpdated

CoreAge Rx
Site position #1

Higher grade

REMEVi
Site position #78

Lower grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 73.5/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +35
92
57
Dose & formulationCoreAge Rx +5
88
83
Clinical oversightCoreAge Rx +7
93
86
Labs & monitoringCoreAge Rx +35
90
55
FulfillmentREMEVi +2
95
97
Contract termsREMEVi +2
67
69
CoreAge Rx · top barREMEVi · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxREMEVi
WeighScore89.5/10073.5/100
GradeB+C
Site position#1#78
SemaglutideProduct page from $79/mo; navigation $99. Confirm selected quote.$219/mo
TirzepatideFrom $129/mo advertised; confirm selected charge, supply and renewal.$319/mo
CoverageUS only; therapy-specific state restrictions applyAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedYes
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
REMEVi

Site position #78 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

What to consider

  • The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard